Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1528-3658

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence ; volume:26 ; number:1 ; day:12 ; month:2 ; year:2020 ; pages:1-9 ; date:12.2020
Molecular medicine ; 26, Heft 1 (12.2.2020), 1-9, 12.2020

Creator: Fontes-Sousa, Mário
Lobo, João
Lobo, Silvana
Salta, Sofia
Amorim, Maria
Lopes, Paula
Antunes, Luís
Sousa, Susana Palma de
Henrique, Rui
Jerónimo, Carmen

Contributor: SpringerLink (Online service)

DOI: 10.1186/s10020-020-0147-5

URN: urn:nbn:de:101:1-2020050921475500323213

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Fontes-Sousa, Mário
Lobo, João
Lobo, Silvana
Salta, Sofia
Amorim, Maria
Lopes, Paula
Antunes, Luís
Sousa, Susana Palma de
Henrique, Rui
Jerónimo, Carmen
SpringerLink (Online service)

Other Objects (12)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Related objects

Reset password